PK14105 has been evaluated biologically as a potential radioligand for positron emission tomography (PET) studies targeting peripheral benzodiazepine binding sites (PBBS) receptors. When administered to rats with unilaterally lesioned striata, PK14105 was observed to quickly cross the blood-brain barrier, displaying significant radioactivity retention in the lesioned striatum, in contrast to the unlesioned striatum or cerebellar vermis. Additionally, PK14105 has the capability to inhibit receptor ligands, calcium channel ligands, and co-transporters in all salivary glands.
Cevimeline HCl is an agonist of cholinergic that binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can enhance the secretion of exocrine glands, such as salivary and sweat glands.
Bufotoxin, a toxic steroid lactone, exists in the parotoid glands, skin, and poison of many toads and other amphibians, and in some plants and mushrooms.
D-Epinephrine can be used as a hormone, neurotransmitter, and medication. Epinephrine can be normally obtained from the adrenal glands and certain neurons. It involves in the fight-or-flight response by increasing blood flow to muscles, output of the hear
Cholesteryl heptadecanoate is a cholesterol ester (CE) formed by the condensation of cholesterol with heptadecanoic acid, a C-17 saturated fatty acid that does not occur in any natural animal or vegetable fat at high concentrations. As such, it is commonly used as an internal standard for the quantification of cholesterol esters by GC- or LC-mass spectrometry. CEs are major constituents of lipoprotein particles carried in blood and accumulate in the fatty acid lesions of atherosclerotic plaques. CEs of various fatty acids are major constituents of murine and human adrenal glands.
CFG920 is a CYP17 inhibitor, is also an orally available inhibitor of the steroid 17-alpha-hydroxylase C17,20 lyase (CYP17A1 or CYP17), with potential antiandrogen and antineoplastic activities. Upon oral administration, CYP17 inhibitor CFG920 inhibits the enzymatic activity of CYP17A1 in both the testes and adrenal glands, thereby inhibiting androgen production. This may decrease androgen-dependent growth signaling and may inhibit cell proliferation of androgen-dependent tumor cells.